Clinical Trial Update: Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age. [Phase 2]

View source ↗

Summary

Phase 2 feasibility study of GSK's GSK2202083A vaccine in healthy infants at 3, 5, and 11 months was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Infection
• Hepatitis B
• Meningococcal Disease
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• GSK2202083A vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Tetanus, Poliomyelitis | Phase 2 | Status: TERMINATED | Results posted: 2017-04-04